Repligen Corporation (NASDAQ:RGEN) Shares Acquired by Bessemer Group Inc.

Bessemer Group Inc. grew its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 1.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 253,014 shares of the biotechnology company's stock after purchasing an additional 4,325 shares during the quarter. Bessemer Group Inc. owned approximately 0.45% of Repligen worth $32,193,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC raised its holdings in shares of Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after purchasing an additional 191,439 shares in the last quarter. Finally, Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 3.4% in the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock valued at $124,727,000 after purchasing an additional 32,665 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Performance

NASDAQ RGEN traded down $0.65 during trading on Friday, reaching $123.56. The company's stock had a trading volume of 851,478 shares, compared to its average volume of 729,092. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of -274.58, a P/E/G ratio of 3.54 and a beta of 1.11. Repligen Corporation has a twelve month low of $102.97 and a twelve month high of $182.52. The business's fifty day moving average price is $128.10 and its 200-day moving average price is $140.82.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.28 earnings per share. As a group, analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RGEN shares. Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Evercore ISI started coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Tuesday, April 29th. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Finally, Royal Bank Of Canada reduced their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, Repligen has an average rating of "Moderate Buy" and an average target price of $172.83.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.